Life Sciences

  • June 09, 2026

    Fed. Circ. 'Recalibrates' Analysis For Constitutional Standing

    The Federal Circuit eased the line between constitutional and statutory standing last month when reviving A.L.M. Holding Co.'s infringement suit against Zydex Industries Private Ltd., in a decision attorneys say makes standing more accessible and clarifies how patent licensors can maintain their rights.

  • June 09, 2026

    4th Circ. Revives Ex-Gilead Worker's Defamation Suit

    The Fourth Circuit revived Tuesday a lawsuit from a former biopharmaceutical company employee after finding that he'd sufficiently backed his claim for vicarious liability against Gilead Sciences Inc., but refused to draw a co-worker back into the case.

  • June 09, 2026

    Eli Lilly Wins Order Halting Alleged Trulicity Fraud

    A Florida federal judge signed off Tuesday on a preliminary injunction pausing a prescription cost share program purportedly for Church of God in Christ members that pharmaceutical giant Eli Lilly and Co. says is actually a fraud scheme to resell GLP-1 drug Trulicity on the secondary market.

  • June 09, 2026

    McKesson, Rite Aid Trust Clash Over Ch. 11 Claims Transfer

    McKesson locked horns Tuesday in New Jersey bankruptcy court with a trust created by Rite Aid's first Chapter 11 plan over whether the medication supplier must hand over antitrust claims against pharmaceutical companies.

  • June 09, 2026

    BioTech Co. Hit Investor Suit Over Cancer Test Trial Miss

    Biotechnology company Grail Inc. was hit with a proposed investor class action alleging that it misled investors about the likelihood its cancer screening blood test would demonstrate effectiveness in a clinical trial, which the public learned in February was unsuccessful.

  • June 09, 2026

    Biopharma Founder's Nonsolicit Clause Void Under Calif. Law

    A biopharmaceutical company's co-founder prevailed Monday in convincing North Carolina's business court that nonsolicitation restrictions in his contract were void after they were deemed unenforceable under California law.

  • June 09, 2026

    Ex-Zydus Unit Exec Alleges 'Second-Class Citizen' Treatment

    A female executive at Zydus Pharmaceuticals' pet health unit said in New Jersey federal court that she was treated as a second-class citizen by her male counterparts, claiming she was constructively discharged due to the hostile and discriminatory conduct she faced because she is a woman.

  • June 09, 2026

    Novanta Buys Riverpoint In $1.45B Deal Steered By 3 Firms

    Medical technology provider Novanta Inc., advised by Ropes & Gray LLP and King & Spalding LLP, on Tuesday announced plans to acquire medical device maker Riverpoint Medical, led by Goodwin Procter LLP, from private equity shop Arlington Capital Partners in a deal worth up to $1.45 billion.

  • June 09, 2026

    4th Circ. Lets Hartford Unit Off The Hook For Drug Test Fight

    A Hartford unit doesn't owe coverage to a drug testing company accused of reporting false positive drug tests due to substandard quality control, the Fourth Circuit ruled Tuesday, saying the suit is related to an earlier claim that was covered by another insurer.

  • June 09, 2026

    The Law360 400: A Look At The Top 100 Firms

    The race to build the legal industry's largest law firm accelerated in 2025, with major firms leaning on mergers, lateral hiring and strategic expansion to climb the ranks of the Law360 400.

  • June 09, 2026

    Davis Polk, Slaughter & May Steer GSK's $10.6B Nuvalent Deal

    Pharma giant GSK PLC said Tuesday that it has agreed to acquire cancer therapy specialist Nuvalent Inc. for $10.6 billion as it seeks to accelerate its "rapid expansion" into the oncology market.

  • June 08, 2026

    Fed. Circ. Scrutinizes UT's 'Inflammatory' Comments In IP Trial

    The "inflammatory" language used by the University of Texas to secure a $42 million patent infringement verdict against Boston Scientific is "about as good an example as one can possibly think of," U.S. Circuit Judge Richard G. Taranto told the university's attorney on Monday.

  • June 08, 2026

    Eli Lilly Conspiracy Claim In Compound Drug Row Challenged

    A California federal court should toss part of Eli Lilly's third attempt at allegations that a telehealth company, provider group and a now-shuttered pharmacy conspired to falsely advertise compounded versions of its weight loss drugs, the companies argued in a recent motion.

  • June 08, 2026

    AIPLA, NAM Rally Behind Moderna's Fight Over Vax Patents

    The American Intellectual Property Law Association, National Association of Manufacturers and others urged the Federal Circuit to undo a lower court's ruling that Moderna, and not the government, must face a multibillion-dollar patent infringement suit over its COVID-19 vaccine.

  • June 08, 2026

    Fed. Circ. Panel Backs Invalidation Of OxyContin Patent

    The Federal Circuit on Monday upheld a Delaware federal court's decision that deemed invalid a Purdue Pharma patent covering an abuse-deterrent version of the opioid OxyContin, rebuffing the company's arguments that the lower court got its obviousness analysis wrong.

  • June 08, 2026

    Biogen To End Investors' Alzheimer's Drug Case For $18.9M

    Biogen Inc. has agreed to pay $18.9 million to exit a lawsuit accusing it of misleading investors about the commercial readiness of a new Alzheimer's treatment, according to a settlement filed in Massachusetts federal court.

  • June 08, 2026

    Goodwin, Fenwick Guide Incyte-Vega Deal Worth Up To $2B

    The biotechnology company Incyte said Monday it has entered into a definitive agreement to acquire Vega Therapeutics Inc. from Star Therapeutics for up to $2 billion, with Goodwin Procter LLP advising Incyte and Fenwick & West LLP representing Star Therapeutics. 

  • June 08, 2026

    Class Attys Want $11.6M In Fees From $35M Teva Inhaler Deal

    Berman Tabacco, Sperling Kenny Nachwalter LLC, Hilliard Shadowen LLP and five other firms have asked a Massachusetts federal judge for $11.55 million in attorney fees from a $35 million antitrust settlement resolving claims that Teva abused patent protections to delay generic competition for its QVAR asthma inhalers.

  • June 08, 2026

    Johnson & Johnson Paying $1B For Oncology Startup Firefly

    Johnson & Johnson said Monday it has agreed to acquire Firefly Bio Inc. for $1 billion in cash, adding a proprietary technology that targets hard-to-treat tumors. 

  • June 08, 2026

    Sleep Aid Buyers Say 'Non-Habit' Pills Can Cause Dependence

    A proposed class of sleep-aid buyers is suing the makers and sellers of Unisom, saying that despite being marketed with a prominent "non-habit forming" claim, its main ingredient has been known to lead to dependence with frequent use.

  • June 05, 2026

    Ex-Trader Accused Of Profiting From Cousin's Insider Info

    A retired New York Mercantile Exchange trader is charged with insider trading by securities regulators who allege he bought shares of Sanofi's biopharmaceutical unit Kadmon Holdings Inc. based on confidential information the trader received about Kadmon's flagship chronic graft-versus-host disease treatment drug in July 2021, and that the trader tipped off a friend about the information.

  • June 05, 2026

    JPML Denies Industrywide Spinal Device Injury MDL Bid

    The Judicial Panel on Multidistrict Litigation declined to consolidate dozens of product liability cases over spinal cord stimulator devices manufactured by Boston Scientific Corp., Abbott Laboratories, Nevro and Medtronic, finding Friday that while centralization of the actions against Boston Scientific was appropriate, an industrywide action was not.

  • June 05, 2026

    Trans Patients Urge Blocking DOJ 'Campaign Of Harassment'

    Transgender adolescents urged a California federal judge Friday to block a Stanford Medicine hospital from sharing gender-related care medical records in response to a Texas grand jury criminal subpoena, arguing that other courts have rebuffed similar government subpoena attempts and the judge should end the DOJ's "campaign of harassment."

  • June 05, 2026

    J&J Cleared Of Talc Liability In LA Bellwether Trial

    A Los Angeles jury cleared Johnson & Johnson of any liability in the deaths of three women from ovarian cancer, finding Friday following a six-week bellwether trial that the company's sales of talcum powder were not negligent. 

  • June 05, 2026

    IRhythm Inks $45M Deal With Investors In Heart Device Suit

    IRhythm Technologies Inc. investors asked a California federal judge to preliminarily greenlight a $45 million settlement resolving allegations the digital healthcare company inflated stock prices with misrepresentations about its heart-event monitoring device, noting the deal is a favorable result that warrants approval, given the possibility of no recovery. 

Expert Analysis

  • FDA User Fee Talks Offer Clues On Upcoming Reforms

    Author Photo

    As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.

  • Moderna Case Highlights Overlooked Hurdle In Biopharma IP

    Author Photo

    The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.

  • FDA Framework For Personalized Therapies Raises Questions

    Author Photo

    The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.

  • Emissions Permits May Not Override Pollution Exclusions

    Author Photo

    Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.

  • 5 Tips For Navigating Your Firm's All-Attorney Summit

    Excerpt from Practical Guidance
    Author Photo

    Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.

  • Series

    Coaching Soccer Makes Me A Better Lawyer

    Author Photo

    Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

  • Avoid The Unexpected When Drafting License Agreements

    Author Photo

    The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.

  • CMS Healthcare Enforcement Initiatives May Cause Disruption

    Author Photo

    The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.

  • The Benefits Of Choosing A Niche Practice In The AI Age

    Author Photo

    As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.

  • How PBMs Can Adapt To Plan Sponsors' Disclosure Demands

    Author Photo

    As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.

  • What New Animal Welfare Enforcement Push Means For Cos.

    Author Photo

    The Trump administration's recently announced multiagency focus on violations of the Animal Welfare Act and related laws will likely lead to broader enforcement actions across industries, heightened scrutiny of compliance standards and a need for businesses to adopt effective risk management practices, says Shennie Patel at Crowell & Moring.

  • How To Engage With Gov't's Direct-To-Consumer Drug Policy

    Author Photo

    The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.

  • Series

    Podcasting Makes Me A Better Lawyer

    Author Photo

    Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.

  • Patent Eligibility Bulletin: Steps To Consider As USPTO Shifts

    Author Photo

    Recent memoranda from the U.S. Patent and Trademark Office, along with some of the first patents issued under Director John Squires, indicate a recalibration of the subject matter eligibility landscape, signaling a renewed emphasis on concrete technological improvements and a potentially pro-AI stance, say attorneys at Banner Witcoff.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.